Abstracts tagged "bone density and treatment"

Abstract Number: 1877 • 2019 ACR/ARP Annual Meeting
Romosozumab Improves Lumbar Spine Bone Mineral Density and Bone Strength Greater Than Alendronate as Assessed by Quantitative Computed Tomography and Finite Element Analysis in the ARCH Trial
Jacques Brown¹, Arkadi Chines ², Roland Chapurlat ³, Joseph Foldes ⁴, Xavier Nogues ⁵, Roberto Civitelli ⁶, Tobias De Villiers ⁷, Fabio Massari ⁸, Cristiano A. Zerbini ⁹, Wenjing Yang ², Chris Recknor ¹⁰ and Cesar Libanati ¹¹, ¹CHU de Quebec Research Centre and Laval University, Quebec, QC, Canada, ²Amgen Inc., Thousand Oaks, CA, ³INSERM UMR 1033, Université de Lyon, Lyon, France, ⁴Hadassah Hebrew University Medical Center, Jerusalem, Israel, ⁵IMIM Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain, ⁶Washington University School of Medicine, St. Louis, MO, ⁷Stellenbosch University, Stellenbosch, South Africa, ⁸Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, ⁹Centro Paulista de Investigação Clinica, São Paulo, Brazil, ¹⁰United Osteoporosis Centers, Gainesville, GA, ¹¹UCB Pharma, Brussels, Belgium
Background/Purpose: Recent evidence suggests BMD achieved during treatment is a reliable surrogate for fracture risk reduction (Bouxsein JBMR 2019). Romosozumab (Romo) is a bone-forming agent…
Abstract Number: 2730 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Romosozumab vs Placebo Among Patients with Mild-to-Moderate Chronic Kidney Disease
Paul Miller¹, Arkadi Chines ², Ben-Hur Albergaria ³, Evelien Gielen ⁴, Bente Langdahl ⁵, Akimitsu Miyauchi ⁶, Mark Vanderkelen ⁷, Cassandra Milmont ², Judy Maddox ² and Jonathan Adachi ⁸, ¹Colorado Center for Bone Research at Panorama Orthopedics and Spine Center, Golden, CO, ²Amgen Inc., Thousand Oaks, CA, ³Federal University of Espirito Santo, Vitória, Brazil, ⁴Gerontology and Geriatrics, Department of Chronic Diseases, Metabolism and Aging, KU Leuven & Center for Metabolic Bone Diseases, UZ Leuven, Leuven, Belgium, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Miyauchi Medical Center, Osaka, Japan, ⁷UCB Pharma, Brussels, Belgium, ⁸McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: Osteoporosis and renal insufficiency are coexisting disease states in a substantial proportion of postmenopausal women. Since bisphosphonates are generally contraindicated in patients with estimated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].